1
|
POS0535 OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING THERAPY WITH ETANERCEPT, ADALIMUMAB, OR JANUS KINASE INHIBITORS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundOngoing debate exists regarding the optimal sequence of tumor necrosis factor inhibitors and Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA) as first-line biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) therapy following conventional therapies.ObjectivesTo describe baseline characteristics, effectiveness, persistency, and treatment patterns among first-line b/tsDMARD-naive initiators of etanercept (ETN), adalimumab (ADA), or JAKis (tofacitinib, baricitinib, and upadacitinib).MethodsData on patients who initiated b/tsDMARD from 11/2012 to 6/2021 were obtained from the CorEvitas RA Registry, a prospective, multicenter, observational, disease-based registry. Patients ≥18 years with rheumatologist-diagnosed RA and 6- and/or 12-months’ (M) follow-up were included. We report descriptive statistics at baseline, persistency on therapy, escalation/de-escalation of therapy, details on patterns of drug switching, and effectiveness outcomes using regression models adjusted for baseline covariates (demographic/socioeconomic/lifestyle characteristics, comorbidities, medication history, disease activity, and patient-reported outcomes). Outcomes were evaluated at 6M and 12M follow-up.ResultsFirst-line initiators of ETN, ADA, and JAKis with baseline and follow-up visits were identified: 803, 984, and 361 patients at 6M, respectively; 589, 749, and 264 patients at 12M, respectively. Baseline characteristics were similar among ETN, ADA, and JAKi initiators with the exception of disease duration, which was longer among first-line JAKi initiators (mean, 8.6 y) versus ETN (5.9 y) and ADA (5.8 y) initiators. Unadjusted mean improvement in Clinical Disease Activity Index (CDAI) was generally similar between groups at 6M and 12M (Table 1). Adjusted effectiveness results were similar at 6M and 12M (Figure 1). At 6M, 68% of ETN, 69% of ADA, and 67% of JAKi initiators remained on the same therapy; at 12M, 53% of ETN, 57% of ADA, and 57% of JAKi initiators remained on the same therapy. The frequency of switching to another b/tsDMARD was similar across initiators.Table 1.Patient Description at Time of Initiation and Unadjusted Disease Activity ResultsETNADAJAKisAge, years54.4 (12.8)55.5 (12.1)60.9 (12.5)Female, n (%)666 (77)843 (76)303 (77)BMI, kg/m230.4 (7.6)31.3 (7.9)30.8 (7.6)Duration of RA, years5.9 (7.6)5.8 (7.3)8.6 (10.0)BL disease activitya CDAI19.9 (14.3)18.9 (12.7)18.8 (13.2) mHAQ0.5 (0.5)0.5 (0.5)0.5 (0.5) Patient painb48.0 (28.8)49.2 (28.5)45.2 (29.2)Disease activity decrease from BL at 6M CDAI6.9 (13.6)6.4 (12.1)4.7 (12.3) mHAQ0.1 (0.4)0.1 (0.4)0.1 (0.4) Patient painb9.7 (30.2)10.6 (28.4)8.9 (29.5)Disease activity decrease from BL at 12M CDAI7.4 (13.5)6.1 (13.0)5.1 (13.0) mHAQ0.1 (0.4)0.1 (0.4)0.1 (0.4) Patient painb8.8 (29.7)8.7 (30.1)7.5 (28.6)Achievement of LDAc, % 6M43.441.932.5 12M41.039.638.3aBaseline for combined population with 6M and 12M follow-up. b(range: 0–100). cCDAI ≤10 among those with moderate or high disease activity at baseline.Data are mean (SD) unless otherwise specified.ADA, adalimumab; BL, baseline; CDAI, Clinical Disease Activity Index; ETN, etanercept; JAKis, Janus kinase inhibitors; LDA, low disease activity; M, months; mHAQ, modified Health Assessment Questionnaire; RA, rheumatoid arthritis; SD, standard deviation.ConclusionIn this real-world study in patients initiating first-line b/tsDMARD therapy with ETN, ADA, or JAKis, we did not observe differences in clinical effectiveness/patient-reported outcomes and treatment persistency at 6M and12M after treatment initiation.AcknowledgementsThis study is sponsored by CorEvitas, LLC. CorEvitas has been supported through contracted subscriptions in the last two years by AbbVie, Amgen Inc., Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, LEO, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Sanofi, Sun, and UCB. Writing support was funded by Amgen Inc. and provided by Su Cappello, PharmD, of Peloton Advantage, LLC, an OPEN Health company, and Julie Wang, DPM, of Amgen Inc.Disclosure of InterestsDimitrios A Pappas Shareholder of: Officer or Board Member for Corrona Research Foundation, Speakers bureau: Speaker/Honoraria for AbbVie, Novartis, Roche Hellas, Sanofi, Consultant of: Consultant for AbbVie, Roche Hellas; Advisor for Sanofi, Employee of: Employment by, ownership interest, and stock options in CorEvitas, LLC, Jacqueline O’Brien Employee of: Employment by CorEvitas, LLC., Lin Guo Employee of: Employment by CorEvitas, LLC., Ying Shan Employee of: Employment by CorEvitas, LLC., Joshua Baker Consultant of: Received consulting fees from Bristol Myers Squibb, Pfizer, CorEvitas LLC, and Burns-White, LLC., Greg Kricorian Shareholder of: Employment by and stock ownership in Amgen Inc., Employee of: Employment by and stock ownership in Amgen Inc., Scott Stryker Shareholder of: Employment by and stock ownership in Amgen Inc., Employee of: Employment by and stock ownership in Amgen Inc., David Collier Shareholder of: Employment by and stock ownership in Amgen Inc., Employee of: Employment by and stock ownership in Amgen Inc.
Collapse
|
2
|
POS0312 REAL-WORLD EVIDENCE ON ASSESSING PSORIATIC ARTHRITIS BY DISEASE DOMAIN: AN EVALUATION OF THE CorEvitas PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS REGISTRY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPsoriatic arthritis (PsA) is a burdensome, chronic disease that can impact patient functionality and quality of life. Real-world data are limited regarding the most common disease domain combinations in patients with PsA receiving biologic disease-modifying anti-rheumatic drugs.ObjectivesThe objective of this study was to describe PsA disease domain frequency, the most common disease domain combinations of PsA manifestations, and pairwise disease domain prevalence in patients initiating treatment with tumor necrosis factor inhibitors (TNFis) or interleukin-17 (IL-17) inhibitors.MethodsThe CorEvitas PsA/Spondyloarthritis (SpA) Registry is a prospective, observational registry for patients with PsA or SpA under the care of a rheumatologist. The current analysis included adults with PsA who initiated treatment with a TNFi (adalimumab, etanercept, certolizumab pegol, infliximab, golimumab), etanercept (ETN; independent exploratory evaluation as a subset of the TNFi group), or an IL-17 inhibitor (ixekizumab, secukinumab) from January 2013 through December 2020. Baseline disease characteristics among the total population and by therapy group were examined for 6 PsA domains, including enthesitis (ET), dactylitis (DA), peripheral arthritis (PA), nail psoriasis (NP), axial PsA (AX), and skin disease (SD). The top 5 most common domain combinations and frequency of other concomitant disease domains within each domain subpopulation are presented.ResultsAmong 1005 patients initiating treatment for PsA (mean age, 52.9 years; 57% female, 90% white), the prevalence of disease domains was PA (86%), SD (82%), NP (57%), ET (38%), DA (23%), and AX (20%); these proportions were similar among the therapy groups. The frequency of high skin disease (body surface area [BSA] ≥10%) at baseline was highest in IL-17 initiators (23% vs 16% for TNFi and 9% for ETN). TNFi (40%) and ETN (48%) were more frequently observed as first-line therapy compared with IL-17 inhibitors (14%). The most common disease domain combination overall (14%) was PA, NP, and SD; frequency of the top 3 most common domain combinations were similar among therapy groups (Table 1). Overall, PA and SD were the most common concomitant disease domains observed within each PsA disease domain subpopulation (Figure 1). Results were similar by therapy group (data not shown).Table 1.Most common PsA domain combinations overall and by therapyDomain Combination Ranking by Frequency, n (%)Overall (N=1005)TNFia (n=631)ETN (n=112)IL-17 (n=374)#1PA, NP, SD 138 (14)PA, NP, SD 91 (14)PA, SD 17 (15)PA, NP, SD 47 (13)#2PA, SD 122 (12)PA, SD 84 (13)ET, PA, NP, SD 13 (12)ET, PA, NP, SD 41 (11)#3ET, PA, NP, SD 95 (9)ET, PA, NP, SD 54 (9)PA, NP, SD 12 (11)PA, SD 38 (10)#4ET, PA, SD 64 (6)DA, PA, NP, SD 38 (6)SD 7 (6)ET, PA, SD 33 (9)#5DA, PA, NP, SD 61 (6)ET, PA, SD 31 (5)ET, PA, NP, AX, SD 6 (5)ET, PA, NP, AX, SD 24 (6)Matching domain combinations are shaded across each therapy group.ET, enthesitis; DA, dactylitis; PA, peripheral arthritis; NP, nail psoriasis; AX, axial PsA; SD, skin disease; TNFi, tumor necrosis factor inhibitors; ETN, etanercept; IL-17, interleukin-17 inhibitors.aTNFi includes ETN initiators.Figure 1.ConclusionThe most common disease domains and domain combinations were similar among initiators of TNFis, ETN, and IL-17s. IL-17 initiators had high skin disease (BSA ≥10%) more often and initiated as first-line therapy less frequently than TNFi initiators. Assessing all PsA domains is important for optimal disease management.AcknowledgementsThis study is sponsored by CorEvitas, LLC. CorEvitas has been supported through contracted subscriptions in the last two years by AbbVie, Amgen Inc., Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, LEO, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Sanofi, Sun, and UCB. Writing support was funded by Amgen Inc. and provided by Jacob Huffman, PhD of Peloton Advantage, LLC, an OPEN Health company, and Julie Wang, DPM, of Amgen Inc.Disclosure of InterestsPhilip J Mease Speakers bureau: AbbVie, Amgen Inc., Eli Lilly, Janssen, Novartis, Pfizer, and UCB – speakers bureau, Consultant of: AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GlaxoSmithKline, Novartis, Pfizer, Sun, and UCB – grant/research support and consultant, Grant/research support from: AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GlaxoSmithKline, Novartis, Pfizer, Sun, and UCB – grant/research support and consultant, Taylor Blachley Employee of: CorEvitas, LLC – employment, Jacqueline O’Brien Employee of: CorEvitas, LLC – employment, Nicole Middaugh Employee of: CorEvitas, LLC – employment, Greg Kricorian Shareholder of: Amgen Inc. – employment and stock ownership, Employee of: Amgen Inc. – employment and stock ownership, Scott Stryker Shareholder of: Amgen Inc. – employment and stock ownership, Employee of: Amgen Inc. – employment and stock ownership, David Collier Shareholder of: Amgen Inc. – employment and stock ownership, Employee of: Amgen Inc. – employment and stock ownership, Alexis Ogdie Shareholder of: Royalties to husband from Novartis, Consultant of: AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, CorEvitas’ Psoriatic Arthritis/Spondyloarthritis Registry (formerly Corrona), Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB – consultant, Grant/research support from: AbbVie, Amgen Inc., Novartis, and Pfizer – grant/research support
Collapse
|
3
|
Application of machine learning classifiers to X-ray diffraction imaging with medically relevant phantoms. Med Phys 2022; 49:532-546. [PMID: 34799852 PMCID: PMC8758543 DOI: 10.1002/mp.15366] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Revised: 10/29/2021] [Accepted: 10/29/2021] [Indexed: 01/03/2023] Open
Abstract
PURPOSE Recent studies have demonstrated the ability to rapidly produce large field of view X-ray diffraction (XRD) images, which provide rich new data relevant to the understanding and analysis of disease. However, work has only just begun on developing algorithms that maximize the performance toward decision-making and diagnostic tasks. In this study, we present the implementation of and comparison between rules-based and machine learning (ML) classifiers on XRD images of medically relevant phantoms to explore the potential for increased classification performance. METHODS Medically relevant phantoms were utilized to provide well-characterized ground-truths for comparing classifier performance. Water and polylactic acid (PLA) plastic were used as surrogates for cancerous and healthy tissue, respectively, and phantoms were created with varying levels of spatial complexity and biologically relevant features for quantitative testing of classifier performance. Our previously developed X-ray scanner was used to acquire co-registered X-ray transmission and diffraction images of the phantoms. For classification algorithms, we explored and compared two rules-based classifiers (cross-correlation, or matched-filter, and linear least-squares unmixing) and two ML classifiers (support vector machines and shallow neural networks). Reference XRD spectra (measured by a commercial diffractometer) were provided to the rules-based algorithms, while 60% of the measured XRD pixels were used for training of the ML algorithms. The area under the receiver operating characteristic curve (AUC) was used as a comparative metric between the classification algorithms, along with the accuracy performance at the midpoint threshold for each classifier. RESULTS The AUC values for material classification were 0.994 (cross-correlation [CC]), 0.994 (least-squares [LS]), 0.995 (support vector machine [SVM]), and 0.999 (shallow neural network [SNN]). Setting the classification threshold to the midpoint for each classifier resulted in accuracy values of CC = 96.48%, LS = 96.48%, SVM = 97.36%, and SNN = 98.94%. If only considering pixels ±3 mm from water-PLA boundaries (where partial volume effects could occur due to imaging resolution limits), the classification accuracies were CC = 89.32%, LS = 89.32%, SVM = 92.03%, and SNN = 96.79%, demonstrating an even larger improvement produced by the machine-learned algorithms in spatial regions critical for imaging tasks. Classification by transmission data alone produced an AUC of 0.773 and accuracy of 85.45%, well below the performance levels of any of the classifiers applied to XRD image data. CONCLUSIONS We demonstrated that ML-based classifiers outperformed rules-based approaches in terms of overall classification accuracy and improved the spatially resolved classification performance on XRD images of medical phantoms. In particular, the ML algorithms demonstrated considerably improved performance whenever multiple materials existed in a single voxel. The quantitative performance gains demonstrate an avenue to extract and harness XRD imaging data to improve material analysis for research, industrial, and clinical applications.
Collapse
|
4
|
OP0101 RHEUMATOID ARTHRITIS DISEASE ACTIVITY OVER TIME AND SUBSEQUENT CARDIOVASCULAR RISKS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular (CV) events not fully explained by traditional CV risk factors. The relationship between fluctuating inflammation due to RA disease activity and CV events is of interest.Objectives:To examine the influence of time-varying disease activity on the subsequent risks of CV disease.Methods:We followed patients from a large US registry of clinically diagnosed RA patients, starting at their first visit with a Clinical Disease Activity Index (CDAI) through the end of follow-up or first CV event. Exposure of interest was disease activity measured by categorical CDAI (high, moderate, low, and remission) averaged within each 6-month window. The outcome of interest was major adverse CV events (MACE) defined as non-fatal myocardial infarction, non-fatal stroke (excluding transient ischemic attacks), and CV death. For baseline confounders we considered age, gender, race, disease duration, Health Assessment Questionnaire, hypertension, diabetes, hyperlipidemia, family history of premature (age<50) CV events, and RF/ACPA seropositivity. For time-varying variables we considered tumor necrosis factor inhibitor (TNFi), non-TNFi biologic, methotrexate, oral glucocorticoid, non-steroidal anti-inflammatory drugs, statin, and aspirin use. We used the marginal structural model (MSM) framework to examine the impact of CDAI at each 6-month interval on MACE. We estimated time-varying hazard ratios (HRs) comparing high CDAI during follow-up to CDAI remission. Several predicted survival curves were constructed under different hypothetical CDAI scenarios, such as early and late transition to CDAI remission.Results:40,721 patients were eligible for our analyses. 77% were female and 84% were Caucasian. The mean age was 58 (SD 13) years with mean disease duration of 8.8 (median 5) years. Mean CDAI at their first registry visit was 14 (SD 13; remission 19%, low 31%, moderate 28%, and high 22%). Other baseline characteristics include: 41% current/former smokers, 31.5% with hypertension, 8.6% with diabetes, 18% with hyperlipidemia, and 52% seropositive. The average follow-up duration after baseline was 4.4 (median 3.3; max. 17.6) years. The crude event count of MACE was 1,050 events / 180,402 person-years.In the MSM analysis, the average HRs, assuming a constant HR, were 1.31 [0.90, 1.90] for low, 1.46 [1.01, 2.10] for moderate, and 1.43 [0.89, 2.31] for high CDAI disease activity categories during each 6-month interval. When approximating time-varying HR with linear trends, the highest estimates during the first 6 months of follow up were 1.61 [0.93, 2.77] for low CDAI, 1.97 [1.13, 3.43] for moderate CDAI, and 2.11 [1.13, 3.96] for high CDAI. These HRs gradually diminished during the follow up (Table). When we constructed hypothetical survival curves with transition to CDAI remission at different time points, earlier transition to CDAI remission was related to better event-free survival (Figure).Table 1.Time-varying hazard ratio estimates [95% confidence intervals] by duration in studyDisease activity measured by CDAIYearRemissionLowModerateHigh0.51.00 [ref]1.61 [0.93, 2.77]1.97 [1.13, 3.43]2.11 [1.13, 3.96]11.00 [ref]1.54 [0.97, 2.44]1.85 [1.17, 2.93]1.94 [1.13, 3.31]21.00 [ref]1.42 [1.00, 2.01]1.63 [1.16, 2.29]1.62 [1.04, 2.54]31.00 [ref]1.31 [0.90, 1.90]1.43 [0.97, 2.11]1.36 [0.80, 2.31]41.00 [ref]1.20 [0.72, 2.02]1.26 [0.72, 2.21]1.14 [0.55, 2.36]51.00 [ref]1.11 [0.54, 2.26]1.11 [0.51, 2.42]0.96 [0.36, 2.53]Figure 1.MACE-free survival curves under hypothetical CDAI scenariosConclusion:High and moderate CDAI were associated with higher hazard of MACE during the earlier period of follow-up, but the increased hazard diminished over time. In hypothetical senarios, earlier transition to CDAI remission would improve MACE free-survival.Acknowledgements:This study was sponsored by Corrona, LLC. Corrona is supported through contracted subscriptions with multiple pharmaceutical companies. The analysis was financially supported by Amgen Inc.Disclosure of Interests:Kazuki Yoshida Consultant of: OM1, Inc., Grant/research support from: Corrona, LLC., Hongshu Guan: None declared, Scott Stryker Shareholder of: Amgen, Inc., Employee of: Amgen, Inc., Elaine Karis Shareholder of: Amgen, Inc., Employee of: Amgen, Inc., Leslie Harrold Consultant of: AbbVie, Bristol-Myers Squibb, Genentech/Roche, Grant/research support from: Pfizer, Daniel Solomon Grant/research support from: DHS receives salary support from research contracts through Brigham and Women’s Hospital with Abbvie, Amgen, Corrona, Genentech and Janssen.
Collapse
|
5
|
Simulation based evaluation of a fan beam coded aperture x-ray diffraction imaging system for biospecimen analysis. Phys Med Biol 2021; 66:065022. [PMID: 33601359 DOI: 10.1088/1361-6560/abe779] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
X-ray diffraction (XRD) imaging yields spatially resolved, material-specific information, which can aid medical diagnosis and inform treatment. In this work we used simulations to analyze the utility of fan beam coded aperture XRD imaging for fast, high-resolution scatter imaging of biospecimens for tissue assessment. To evaluate the proposed system's utility in a specific task, we employed a deterministic model to produce simulated data from biologically realistic breast tissue phantoms and model-based reconstruction to recover a spatial map of the XRD signatures throughout the phantoms. We found an XRD spatial resolution of ≈1 mm with a mean reconstructed spectral accuracy of 0.98 ± 0.01 for a simulated 1 × 150 mm2 fan beam operating at 160 kVp, 10 mA, and 4.5 s exposures. A classifier for cancer detection was developed utilizing cross-correlation of XRD spectra against a spectral library, with a receiver operating characteristic curve with an area under the curve value of 0.972. Our results indicated a potential diagnostic modality that could aid in tasks ranging from analysis of ex-vivo pathology biospecimens to intraoperative cancer margin assessment, motivating future work to develop an experimental system while enabling the development of improved algorithms for imaging and tissue analysis-based classification performance.
Collapse
|
6
|
SAT0150 CHANGES IN PATIENT-REPORTED OUTCOME (PRO) SCORES FOR NAUSEA AND FATIGUE FOLLOWING WEEKLY METHOTREXATE DOSE IN A REAL-WORLD SAMPLE OF RA AND PSA PATIENTS IN THE ARTHRITISPOWER REGISTRY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Methotrexate (MTX) is frequently used in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) because of its beneficial effects in both populations1-3. Despite the well-known benefits of MTX, it is associated with a number of potential side effects4-6These include nausea and fatigue, are often temporally related to the timing of weekly MTX administration, and can be severe. The combined patient-reported side effects, along with potential of long-term toxicity, may make use of MTX more burdensome. Currently, there is a gap in patient-centered studies that focus on patients’ experience with MTX.Objectives:Examine patient temporal experience of fatigue and nausea relating to oral MTX therapy for the treatment of RA and PsA.Methods:Adult US patients in the ArthritisPower registry with self-reported RA or PsA taking MTX for less than 10 years were invited to participate in the study via email invitation. Participants (pts) completed a screener and brief online survey. In an ancillary study to the ArthritisPower registry and using a self-controlled case series study design where pts serve as their own control to avoid between-person confounding, pts were asked to complete a set of up to 8 assessments within 6-36 hours (‘risk’) and 96-144 hours (‘control’) after taking their oral dose of MTX each week, for up to 4 weeks. Risk and control windows were selected based on the expected temporal relationship between MTX use and peak onset of these symptoms. Assessments included PROMIS short forms for same-day Fatigue, same-day Nausea/Vomiting, and Patient Global. Descriptive statistics were conducted using paired t-tests two-way comparisons. Within-person change in PROMIS scores between the risk (1-2 days after MTX) and control (4-6 days after MTX) windows were analyzed using mixed models for repeated measures, stratified on whether pts reported fatigue or nausea with MTX at baseline. Recruitment for this study is ongoing.Results:As of December 2019, 91 pts had participated, of whom 76.9% were living with RA and 28.6% with PsA, with mean baseline PROMIS Patient Global score (SD) of 39.5 (7.1). Mean age (SD) was 50.9 (12.0) years, 84.6% female, 92.3% White, with mean BMI 33.7 (8.8). Mean duration of MTX treatment among current users was 2.1 (2.8) years. Among pts, 41.8% were on a biologic DMARD and 58.2% on non-biologic DMARDs only. Among pts reporting baseline nausea (n=30, 33.0%) where paired within-week measures were observed (n=64 observations among 20 pts), the mean increase in the PROMIS Nausea score was 4.5 units (adjusted p=0.003). Among those reporting MTX-associated fatigue (n=39, 42.9%) as a side effect of MTX on their baseline survey where paired within-week measures were observed (n=96 observations among 28 pts), the mean increase in PROMIS Fatigue was 4.7 (adjusted p=0.004) units. In those pts, the proportion of pts with worsened nausea and fatigue with minimally important difference of >5 units7-8was 40.0% (nausea), and 60.7% (fatigue) [Figures 1 and 2].Conclusion:People taking MTX to manage RA or PsA commonly experience bothersome side effects, notably fatigue and nausea, that are temporally related to weekly MTX dosing. In this sample, one-third or more of pts were bothered by nausea or fatigue shortly after MTX dosing, many of them with clinically meaningful symptoms.References:[1]Singh JA, et al.Arthritis Rheumatol. 2016;68:1-26.[2]Singh JA, et al.Arthritis Rheumatol. 2019;71:5-32.[3]Mease P.Bull NYU Hosp Jt Dis. 2013;71.(suppl 1):S41.[4]Wang W, et al.Eur J Med Chem. 2018;158:502-516.[5]Wilsdon TD, et al.Cochrane Database Syst Rev. 2019;1:CD012722.[6]Husted JA, et al.Ann Rheum Dis. 2009;68:1553-1558.[7]Norman GR, et al.Med Care. 2003;41:582-92.[8]Bingham CO, et al.J Patient Rep Outcomes. 2019;3:14.Disclosure of Interests:W. Benjamin Nowell: None declared, Elaine Karis Shareholder of: Amgen Inc., Employee of: Amgen Inc., Kelly Gavigan: None declared, Laura Stradford: None declared, Scott Stryker Shareholder of: Amgen Inc., Employee of: Amgen Inc., Huifeng Yun Grant/research support from: Bristol-Myers Squibb and Pfizer, Shilpa Venkatachalam: None declared, Greg Kricorian Shareholder of: Amgen Inc., Employee of: Amgen Inc., Lang Chen: None declared, Hong Zhao: None declared, Fenglong Xie: None declared, Jeffrey Curtis Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Regeneron, Roche, UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Regeneron, Roche, UCB
Collapse
|
7
|
Monte Carlo dosimetry modeling of focused kV x-ray radiotherapy of eye diseases with potential nanoparticle dose enhancement. Med Phys 2018; 45:4720-4733. [PMID: 30133705 DOI: 10.1002/mp.13144] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2018] [Revised: 08/14/2018] [Accepted: 08/14/2018] [Indexed: 12/18/2022] Open
Abstract
PURPOSE Eye plaque brachytherapy is the most common approach for intraocular cancer treatment. It is, however, invasive and subject to large setup uncertainty due to the surgical operation. We propose a novel-focused kV x-ray technique with potential nanoparticle (NP) enhancement and evaluate its application in treating choroidal melanoma and iris melanoma by Monte Carlo (MC) dosimetry modeling. METHODS A polycapillary x-ray lens was used to focus 45 kVp x rays to achieve pinpoint accuracy of dose delivery to small tumors near critical structures. In addition to allowing for beam focusing, the use of kV x rays takes advantage of the strong photoelectric absorption of metallic NPs in that energy regime and hence strong radiosensitization. We constructed an MC simulation program that takes into account the x-ray optic modeling and used GEANT4 for dosimetric calculation. Extensive phantom measurements using a prototype-focused x-ray system were carried out. The MC simulation of simple geometry phantom irradiation was first compared to measurements to verify the x-ray optic lens modeling in conjunction with the Geant4 dosimetric calculation. To simulate tumor treatment, a geometric eye model and two tumor models were constructed. Dose distributions of the simulated treatments were then calculated. NP radiosensitization was also simulated for two concentrations of 2 nm gold NP (AuNP) uniformly distributed in the tumor. RESULTS The MC-simulated full width at half maximum (FWHM) and central-axis depth dose of the focused kV x-ray beam match those measured on EBT3 films within ~10% around the depth of focus of the beam. Dose distributions of the simulated ocular tumor treatments show that focused x-ray beams can concentrate the high-dose region in or close to the tumor plus margin. For the simulated posterior choroidal tumor treatment, with sufficient tumor coverage, the doses to the optic disc and fovea are substantially reduced with focused x-ray therapy compared to eye plaque treatment (3.8 vs 39.8 Gy and 11.1 vs 53.8 Gy, respectively). The eye plaque treatment was calculated using an Eye Physics plaque with I-125 seeds under TG43 assumption. For the energy spectrum used in this study, the average simulated dose enhancement ratios (DERs) are roughly 2.1 and 1.1 for 1.0% and 0.1% AuNP mass concentration in the tumor, respectively. CONCLUSION Compared to eye plaque brachytherapy, the proposed focused kV x-ray technique is noninvasive and shows great advantage in sparing healthy critical organs without sacrificing the tumor control. The NP radiation dose enhancement is considerable at our proposed kV range even with a low NP concentration in the tumor, providing better critical structure protection and more flexibility for treatment planning.
Collapse
|
8
|
On the use of bolus for pacemaker dose measurement and reduction in radiation therapy. J Appl Clin Med Phys 2017; 19:125-131. [PMID: 29152840 PMCID: PMC5768029 DOI: 10.1002/acm2.12229] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Revised: 10/16/2017] [Accepted: 10/23/2017] [Indexed: 11/09/2022] Open
Abstract
Special attention is required in planning and administering radiation therapy to patients with cardiac implantable electronic devices (CIEDs), such as pacemaker and defibrillator. The range of dose to CIEDs that can induce malfunction is large among CIEDs. Clinically significant defects have been reported at dose as low as 0.15 Gy. Therefore, accurate estimation of dose to CIED and dose reduction are both important even if the dose is expected to be less than the often-used 2-Gy limit. We investigated the use of bolus in in vivo dosimetry for CIEDs. Solid water phantom measurements of out-of-field dose for a 6-MV beam were performed using parallel plate chamber with and without 1- to 2-cm bolus covering the chamber. In vivo dosimetry at skin surface above the CIED was performed with and without bolus covering the CIED for three patients with the CIED <5 cm from the field edge. Chamber measured dose at depth ~0.5-1.5 cm below the skin surface, where the CIED is normally located, was reduced by ~7-48% with bolus. The dose reduction became smaller at deeper depths and with smaller field size. In vivo dosimetry at skin surface also indicated ~20%-60% lower dose when using bolus for the three patients. The dose measured with bolus more accurately reflects the dose to CIED and is less affected by contaminant electrons and linac head scatter. In general, the treatment planning system (TPS) calculation underestimated the dose to CIED, but it predicts the CIED dose more accurately when bolus is used. We recommend the use of 1- to 2-cm bolus to cover the CIED during in vivo CIED dose measurements for more accurate CIED dose estimation. If the CIED is placed <2 cm in depth and its dose is mainly from anterior beams, we recommend using the bolus during the entire course of radiation delivery to reduce the dose to CIED.
Collapse
|
9
|
Population-Based Study of Giant Cell Tumour of the Bone in Sweden. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu354.49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
|
11
|
31 INVITED Five year results from the COST trial testing laparoscopic versus open colectomy for colon cancer. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70145-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
12
|
Abstract
An unusual case of deciduoid mesothelioma occurring in the anterior abdominal wall of a 30-year-old woman is reported. The patient had a palpable mass that was resected. The mass appeared largely cystic with solid areas. Histologically, the tumor cells appeared epitheloid with eosinophilic cytoplasm and prominent nucleoli. The tumor was positive for keratins and vimentin and negative for CEA and Ber-EP4. Electron microscopy showed features of mesothelial cells characterized by well-formed desmosomes and long, slender microvilli. In contrast to previously reported cases of deciduoid mesothelioma, this tumor developed in the abdominal wall and appears to have a benign course.
Collapse
|
13
|
Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999; 28:231-41. [PMID: 10497371 DOI: 10.1002/(sici)1099-0496(199910)28:4<231::aid-ppul1>3.0.co;2-2] [Citation(s) in RCA: 139] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Cystic fibrosis (CF) is a complex illness characterized by chronic lung infection leading to deterioration in function and respiratory failure in over 85% of patients. An understanding of the risk factors for that progression and the interaction of these factors with current therapeutic strategies should materially improve the prevention of this progressive lung disease. The Epidemiologic Study of Cystic Fibrosis (ESCF) was therefore designed as a multicenter, longitudinal, observational study to prospectively collect detailed clinical, therapeutic, microbiologic, and lung function data from a large number of CF treatment sites in the U.S. and Canada. The ESCF also serves an important role as a phase-IV study of dornase alfa. To be eligible for enrollment, subjects must have the diagnosis of CF and receive the majority of their care at an ESCF site. In this paper, the authors present the ESCF study design in detail. Further, enrollment data collected at 194 study sites in 18,411 subjects enrolled from December 1, 1993 to December 31, 1995 are presented in summary form. This comprehensive study is unique in the detail of clinical data collected regarding patient monitoring and therapeutic practices in CF care. Two companion articles present data regarding practice patterns in cystic fibrosis care, including data on resource utilization and prescribing practices.
Collapse
|
14
|
A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998; 91:3509-17. [PMID: 9558412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
An observational study was conducted at 18 transplant centers in the United States and Canada to characterize the platelet recovery of patients receiving myeloablative therapy and stem cell transplantation and to determine the clinical variables influencing recovery, determine platelet utilization and cost, and incidence of hemorrhagic events. The study included 789 evaluable patients transplanted in 1995. Clinical, laboratory, and outcome data were obtained from the medical records. Variables associated with accelerated recovery in multivariate models included (1) higher CD34 count; (2) higher platelet count at the start of myeloablative therapy; (3) graft from an HLA-identical sibling donor; and (4) prior stem cell transplant. Variables associated with delayed recovery were (1) prior radiation therapy; (2) posttransplant fever; (3) hepatic veno-occlusive disease; and (4) use of posttransplant growth factors. Disease type also influenced recovery. Recipients of peripheral blood stem cells (PBSC) had faster recovery and fewer platelet transfusion days than recipients of bone marrow (BM). The estimated average 60-day platelet transfusion cost per patient was $4,000 for autologous PBSC and $11,000 for allogeneic BM transplants. It was found that 11% of all patients had a significant hemorrhagic event during the first 60 days posttransplant, contributing to death in 2% of patients. In conclusion, clinical variables influencing platelet recovery should be considered in the design and interpretation of clinical strategies to accelerate recovery. Enhancing platelet recovery is not likely to have a significant impact on 60-day mortality but could significantly decrease health care costs and potentially improve patient quality of life.
Collapse
|
15
|
Early results of laparoscopic surgery for colorectal cancer. Retrospective analysis of 372 patients treated by Clinical Outcomes of Surgical Therapy (COST) Study Group. Dis Colon Rectum 1996; 39:S53-8. [PMID: 8831547 DOI: 10.1007/bf02053806] [Citation(s) in RCA: 208] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
UNLABELLED This study was undertaken to determine the early experience of the embers of the COST Study Group with colorectal cancer treated by laparoscopic approaches. METHOD A retrospective review was performed of all patients with colorectal cancer treated with laparoscopy by the COST Study Group before August 1994. Tumor site, stage, differentiation, procedure completion, presence of recurrence (local, distant, trocar site), and cause of death were analyzed. RESULTS A total of 372 patients with adenocarcinoma of the colon and rectum were treated by laparoscopic approach between October 1991 and August 1994 (170 men and 192 women): right colectomy, 170; sigmoid colectomy, 55; low anterior resection, 56; abdominoperineal resection, 44; left colectomy, 22; colostomy, 8; total colectomy, 6; transverse colectomy, 7; exploration, 2. Conversion to an open procedure was required in 15.6 percent of cases. Operative mortality was 2 percent. Tumor characteristics were as follows: TNM state: I, 40 percent; II, 25 percent; III, 18 percent; IV, 17 percent; Differentiation: well-moderate, 88 percent; poor, 12 percent; carcinomatosis, 5 percent. Local (3.6 percent) and distant implantation occurred in four patients (1.1 percent). Only one of these patients died a cancer-related death (Stage III at 36 months). Cancer-related death rates increased with increasing stage of tumor: I, -4 percent; II, 17 percent; III, 31 percent; IV, 70 percent. CONCLUSION A laparoscopic approach to colorectal cancer results in early outcome after treatment that is comparable with conventional therapy for colorectal cancer. A randomized trial is needed to compare long-term outcomes of open and laparoscopic approaches with colorectal cancer.
Collapse
|
16
|
Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. THE AMERICAN JOURNAL OF PATHOLOGY 1994; 145:1291-5. [PMID: 7992834 PMCID: PMC1887505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
To evaluate the incidence and stage at which p53 alterations occur in human pancreatic carcinogenesis, we examined primary and metastatic carcinomas, carcinoma in situ, and hyperplastic lesions with and without atypia for p53 protein overexpression by immunohistochemical procedure. Overexpression of p53 was observed in 40% (10/25) of primary tumors, 29% (2/7) of metastatic tumors, 36% (5/14) of carcinoma in situ, and 35% (6/17) of hyperplastic lesions. These results suggest that p53 protein overexpression is not only a common genetic alteration but also occurs very early in the development of these tumors. It is suggested that p53 overexpression can be used as a marker to identify precursor lesions that have increased potential to develop into malignant tumors.
Collapse
|
17
|
Abstract
Data from the 1969 and 1971 panels of the National Longitudinal Survey of Middle-Aged Men are analyzed to assess the mediating effects of locus of control beliefs in the relationship between stressful job and economic events and psycho-physiological well-being. The analyses indicate that men with internal locus of control orientations respond more adequately to stress than do those with external locus of control beliefs. A more detailed examination of the data revealed that men with moderately internal locus of control orientations cope more effectively with stress than those whose locus of control beliefs may be classified as extreme internal, extreme external or moderately external. The theoretical implications of these findings are discussed.
Collapse
|
18
|
|
19
|
Abstract
The case of an 18-year-old man with coarctation of the aorta discovered on routine physical examination and subsequently surgically repaired is reported. Four months postoperatively, aneurysms developed at the repair site and thrombosis of both femoral arteries was noted. Following an attempt to repair the aneurysm and remove the thrombi, the patient became paraplegic; Aspergillus fumigatus was found infecting the aorta and femoral vessels. After additional operations and a course of amphotericin B to control the fungal infection, the patient died of intrathoracic bleeding originating from infected, aneurysmally dilated intercostal vessels in the area of the original coarctation repair. The complicating fungal infection of the operative site and the paraplegia are discussed. This report is among the first to present a patient with fungal endarteritis complicating operation for coarctation of the aorta.
Collapse
|
20
|
Abstract
A cluster of five cases of non-O group 1 (non-O1) V. cholerae gastroenteritis occurred in one Florida locality during November 1979. Clinical findings included nausea, vomiting, and abdominal cramping in all affected persons; two had bloody diarrhea. All five persons gave a history of eating raw oysters within four days of onset of illness. A case-control study statistically associated the eating of raw oysters with development of illness (p = 0.0008); this finding was confirmed by a retrospective cohort study of patients hospitalized for diarrhea (p = 0.0001). Non-O1 V. cholerae organisms were isolated from oysters and water samples taken from areas where ill persons had obtained their oysters. In at least one instance the same serotype was isolated from a patient's stool specimen and from the water where the patient had obtained oysters. Non-O1 V. cholerae infection must be considered in the differential diagnosis of shellfish-associated gastroenteritis.
Collapse
|
21
|
Mesenteric tumefactions. Am Surg 1980; 46:525-9. [PMID: 7416634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Mesenteric tumefactions comprise a group of non-neoplastic conditions that present as an intra-abdominal mass. Symptoms vary from none to obstruction of the gastrointestinal tract. Histologic examination reveals dystrophy, fibrosis, or inflammation of the mesenteric fat. Despite a large number of descriptive terms currently in use, this study suggests that all these lesions are part of a single clinical and histologic continuum.
Collapse
|
22
|
Procedures relating to Medicare and other third-party payments. ASHA 1976; 18:491-5. [PMID: 791296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
23
|
A note on self conception and the emotionally disturbed role. SOCIOMETRY 1966; 29:300-5. [PMID: 5920058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|